GO
Loading...

No. 2 - Bio-Hazard

Monday, 14 May 2007 | 1:08 PM ET

Sometimes the stocks that trade on hope lead only to despair. Investors in biotech companies Amgen (AMGN) and Dendreon (DNDN) suffered serious side effects this week as the FDA raised questions about the safety and effectiveness of their flagship drugs.

Shares of Amgen plunged the most in 5 years yesterday as the future of its anemia medications came into doubt, while Dendreon shares shed nearly 70% of their value this week on concerns about its prostate cancer drug.

Meanwhile, the iShares NASDAQ Biotechnology Index (IBB) tumbled 4% for the week on the news. Is there any hope for the sector that trades on hope?

CNBC Pharmaceuticals Reporter Mike Huckman joins the guys for the conversation.

The Top Three #2
A biotech outlook with CNBC's Mike Huckman

Mike explains that the annual meeting of the American Society of Clinical Oncology (ASCO) begins June 1st. This is the most highly anticipated scientific medical conference of the year, Mike adds.

At ASCO, Imclone (IMCL) will present data on its cancer drug. Celgene (CELG) will present data on its blood cancer drug and Onyx Pharma (ONXX) will present data on a kidney cancer drug.

Dylan asks if any stocks are trading higher ahead of the conference.

Onyx and Celegene, Mike replies.

Then Mike cautions investors about trading the news because information about these drugs is distributed in blocks ahead of time, to different groups of people such as doctors and the media.

Dylan adds, investors could see these stocks run long before anything happens.

Karen Finerman says that’s probably the most important point.

Guy Adami tells the panel in the bio-tech space he likes the 3 G’s -- Genentech (DNA) as well as Gilead (GILD) and Geron (GERN).

Got something to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to fastmoney@cnbc.com.

Trader disclosure: On May 11, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders;Bolling Owns (ICE), (NMX),Gold, Silver; Finerman and/or her Firm Owns (BBI), (KBR), (HD), (FLS), (CX), (ASD), (WMT), (TYC), (GS), (INWK); Finerman's Firm Is Short (HAL)

  Price   Change %Change
GERN
---
GILD
---
OX1
---
CELG
---
DNDN
---
AMGN
---

Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET
  • Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

  • Scott Wapner is host of the "Fast Money Halftime Report," which airs weekdays from 12 p.m. to 1 p.m. ET.

  • Guy Adami is a contributor on CNBC's "Fast Money." He also is managing director of stockMONSTER.com.

  • Najarian, the "Pit Boss," is cofounder of optionMONSTER.com, a news site for options traders.

  • Finerman is president of Metropolitan Capital Advisors, Inc., a company she co-founded.

  • Founder of EmergingMoney.com

  • Chief Market Strategist for Virtus Investment Partners & CNBC Contributor

Halftime Report